J Bacteriol Virol.  2017 Jun;47(2):102-104. 10.4167/jbv.2017.47.2.102.

Texiobactin, a Potent Killer of Antibiotic Resistant Pathogens

• Arooj M
• Koh YS

• KMID: 2384413
• DOI: http://doi.org/10.4167/jbv.2017.47.2.102

Abstract

Antibiotic resistance is a major global concern that primarily affects public health. Texiobactin is a newly discovered antibiotic produces by soil microbes isolated from natural environment. Drug is active against Gram-positive bacteria as it inhibits biosynthesis of peptidoglycan. Infection of methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae in mice elicits a good response reduce bacterial load. Although extensive efforts have been made to discover new antibiotics but results are still not satisfactory to meet the demands of public health. Recently it has been shown that the discovery of texiobactin by iChip will be a great stone mile to discover more antibiotics.

Keyword

Texiobactin; Peptidoglycan; MRSA; iChip

MeSH Terms

Animals
Anti-Bacterial Agents
Bacterial Load
Drug Resistance, Microbial
Gram-Positive Bacteria
Methicillin-Resistant Staphylococcus aureus
Mice
Peptidoglycan
Public Health
Soil
Streptococcus pneumoniae
Anti-Bacterial Agents
Peptidoglycan
Soil

Reference

1). Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015; 517:455–9.

2). Pham VH, Kim J. Cultivation of unculturable soil bacteria. Trends Biotechnol. 2012; 30:475–84.

3). Wright G. Antibiotics: An irresistible newcormer. Nature. 2015; 517:442–4.

4). Nichols D, Cahoon N, Trakhtenberg EM, Pham L, Mehta A, Belanger A, et al. Use of Ichip for High-Throughput In Situ Cultivation of "Uncultivable" Microbial Species. Appl Environ Microbiol. 2010; 76(2445):50.

5). Willems RJ, Homan W, Top J, van Santen-Verheuvel M, Tribe D, Manzioros X, et al. Variant esp gene as a maker of a distinct genetic lineage of vancomycin-resistant Enterococcus faecium spreading in hospitals. Lancet. 2001; 357:853–5.

6). Hendrickx AP, Bonten MJ, van Luit-Asborek M, Schapendonk CM, Kragten AH, Willems RJ. Expression of two distinct types of pili by a hospital-acquired Enterococcus faecium isolate. Microbiology. 2008; 154:3212–23.

7). Hendrickx AP, van Wamel WJ, Posthuma G, Bonten MJ, Willems RJ. Five genes encoding surface-exposed LPXTG proteins are enriched in hospital-adapted Enterococcus faecium clonal complex 17 isolates. J Bacteriol. 2007; 189:8321–32.

8). Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012; 10:266–78.

9). Holler E, Butzhammer P, Schmid K, Hundsrucker C, Koestler J, Peter K, et al. Metagenomics analysis of stool microbiome in patients receiving allogenic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2014; 20:640–5.

10). Homma T, Nuxoll A, Gandt AB, Ebner P, Engels I, Schneider T, et al. Dual Targeting of Cell Wall Precursors by Teixobactin Leads to Cell Lysis. Antimicrob Agents Chemother. 2016; 60:6510–17.

11). Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature. 2011; 469:543–7.